Hemostemix Inc. (CVE:HEM – Get Free Report) shares were up 19% during mid-day trading on Wednesday . The company traded as high as C$0.13 and last traded at C$0.13. Approximately 291,000 shares traded hands during trading, a decline of 13% from the average daily volume of 332,835 shares. The stock had previously closed at C$0.11.
Hemostemix Price Performance
The business has a 50 day simple moving average of C$0.09 and a 200 day simple moving average of C$0.07. The stock has a market cap of C$12.63 million, a PE ratio of -7.25 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Pros And Cons Of Monthly Dividend Stocks
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- How to Start Investing in Real Estate
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- What Are Earnings Reports?
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
